Trial Profile
A MULTICENTRE DOUBLE-BLIND RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND TOLERABILITY OF GS-101 EYE DROPS, AN ANTISENSE OLIGONUCLEOTIDE, VERSUS PLACEBO ON INHIBITION OF CORNEAL NEOVASCULARIZATION, A MAJOR RISK FACTOR OF CORNEAL GRAFT REJECTION: The I-CAN study.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2016
Price :
$35
*
At a glance
- Drugs Aganirsen (Primary)
- Indications Corneal neovascularisation; Keratitis
- Focus Therapeutic Use
- Acronyms I-CAN; I-GRAFT
- Sponsors Laboratoires CTRS
- 29 Jul 2015 New trial record